Idera Pharmaceuticals

Idera Pharmaceuticals is a biopharmaceutical company focused on the clinical development and commercialization of drug candidates for both oncology and rare disease indications. The company's focus is on its Toll-like receptor (TLR), agonist, tilsotolimod (IMO-2125), for oncology. The company is developing tilsotolimod, via intratumoral injection, for the treatment of anti-PD1 refractory metastatic melanoma in combination with ipilimumab, an anti-CTLA4 antibody marketed as Yervoy? by Bristol-Myers Squibb Company (BMS). The company is also evaluating intratumoral tilsotolimod in combination with nivolumab, an anti-PD1 antibody marketed as Opdivo? by BMS, and ipilimumab for the treatment of multiple solid tumors.
  • TickerIDRA
  • ISINUS45168K4058
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States
Robert Driscoll ... (+2)
  • Robert Driscoll
  • Ashiq Mubarack
Robert Driscoll ... (+2)
  • Robert Driscoll
  • Ashiq Mubarack
Robert Driscoll ... (+2)
  • Robert Driscoll
  • Ashiq Mubarack
Robert Driscoll ... (+2)
  • Robert Driscoll
  • Ashiq Mubarack
Robert Driscoll ... (+2)
  • Robert Driscoll
  • Ashiq Mubarack
Robert Driscoll ... (+2)
  • Robert Driscoll
  • Ashiq Mubarack
Robert Driscoll ... (+2)
  • Robert Driscoll
  • Ashiq Mubarack
Robert Driscoll ... (+2)
  • Robert Driscoll
  • Ashiq Mubarack
Robert Driscoll ... (+2)
  • Robert Driscoll
  • Ashiq Mubarack
Robert Driscoll ... (+2)
  • Robert Driscoll
  • Ashiq Mubarack

ResearchPool Subscriptions

Get the most out of your insights

Get in touch